

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>

Prion hypothesis: the end of the controversy?

Claudio Soto

Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, The University of Texas Medical School at Houston, 6431 Fannin St, Houston, TX 77030, USA

Forty-three years have passed since it was first proposed that a protein could be the sole component of the infectious agent responsible for the enigmatic prion diseases. Many discoveries have strongly supported the prion hypothesis, but only recently has this once heretical hypothesis been widely accepted by the scientific community. In the past 3 years, researchers have achieved the 'Holy Grail' demonstration that infectious material can be generated *in vitro* using completely defined components. These breakthroughs have proven that a misfolded protein is the active component of the infectious agent, and that propagation of the disease and its unique features depend on the self-replication of the infectious folding of the prion protein. In spite of these important discoveries, it remains unclear whether another molecule besides the misfolded prion protein might be an essential element of the infectious agent. Future research promises to reveal many more intriguing features about the rogue prions.

The mysterious prion diseases

Prion diseases are a group of fatal and infectious neurodegenerative diseases that affect humans and diverse animal species [1]. The infectious nature of prion diseases was first evident more than 70 years ago when accidental transmission of scrapie occurred in sheep. Inoculation against a common virus with a formalin extract of tissue that was unknowingly derived from an animal with scrapie infected nearly 10% of the flock. Scrapie was subsequently transmitted experimentally to sheep [2] and later to mice [3]. In humans, an infectious origin was suspected for kuru, a prion disease identified in some cannibalistic tribes of New Guinea; a formal demonstration came in 1966 with the transmission of kuru to monkeys [4]. These studies were followed by transmission of Creutzfeldt–Jakob disease (CJD) [5] and Gerstmann–Straussler–Scheinker syndrome, an inherited form of prion disease, to primates [6]. These discoveries added to the initial findings that suggested that the infectious agent responsible for these diseases was different from any known form of microorganism, and led to a plethora of research that was aimed at understanding the nature of the agent. A second boost in the prion field came when an outbreak of bovine spongiform encephalopathy (BSE) in cattle in the UK was shown to be mediated by prion infection [7]. Between the discovery of this disease as a prion disorder and the implementation of measures to prevent possible transmission to humans, it is likely that the entire popula-

tion of the UK and a large part of the European population might have consumed infected meat. These initial concerns were confirmed when a new form of human disease, termed variant CJD, appeared and was convincingly linked to BSE [8,9]. This article focuses on recent advances regarding the nature of the infectious agent that is responsible for prion diseases and the mechanisms of prion propagation.

A historical perspective of the prion hypothesis

Starting from the initial discoveries in the prion field, it was clear that the infectious agent responsible for prion diseases was different from conventional microorganisms. Over decades of research, many milestone discoveries have provided crucial evidence in favor of the prion hypothesis, which proposes that a misfolded protein is the main (and perhaps the sole) component of this unorthodox infectious agent called a prion (Figure 1). In a series of key experiments, Alper and co-workers demonstrated that procedures that obliterate nucleic acids, such as very high doses of ionizing radiation and UV, do not destroy the infectious material [10,11]. The same group also reported that the minimum molecular weight to maintain infectivity ($\sim 2 \times 10^5$ Da) is too small to be a virus or other type of microorganism [12]. This estimate is in the range of the size of most infectious prion particles that are obtained with modern sophisticated techniques [13]. Based on these observations, speculation arose that the infectious agent might be protein-based [14]. In 1967, Griffith proposed three scenarios by which a protein could act as the infectious agent that causes scrapie [15]. However, little research was done to test this hypothesis until Prusiner and coworkers pioneered an impressive set of discoveries that gave fuel to the prion hypothesis, and coined the term prion to refer to this heretical proteinaceous infectious agent [16].

In landmark research, the protease-resistant prion protein (PrP^{Sc}) was isolated from the infectious material [17]. PrP^{Sc} and infectivity co-purified, and the protein concentration was proportional to the infectivity titer [18]. These breakthroughs radically changed the prion field, and much effort then turned to study this protein. Infectivity was shown to be retained in highly purified preparations of PrP^{Sc}, in which no other protein was detectable, although the sample did contain lipids and carbohydrates, and perhaps nucleic acids. Importantly, infectivity is reduced by agents that destroy protein structure, and strikingly, by anti-PrP antibodies [18]. The gene that encodes PrP (PRNP) was identified in the mammalian genome [19,20], and the corresponding mRNA was shown to be

Corresponding author: Soto, C. (Claudio.Soto@uth.tmc.edu).




Figure 1. A timeline representation of the major milestones in the prion hypothesis. Starting with the initial indication that prion diseases can be transmissible, owing to the accidental transmission of scrapie in sheep, and ending with the demonstration that infectious material can be generated *in vitro* using pure recombinant prion protein, the prion field has always been full of unorthodox discoveries.

the product of a single host gene, which is expressed mostly in the brain, without significant changes in expression in healthy or infected animals. These findings indicated that the prion protein can exist as both a normal cellular protein (termed PrP^C) and a pathological isoform (termed PrP^{Sc}) [21]. Surprisingly, no chemical differences can be detected between the two forms of the protein; rather, the nature of their distinct properties appears to be enciphered in the conformation adopted by the proteins [22]. Once *PRNP* was identified, genetic analyses discovered the first *PRNP* mutation linked to familial prion disease [23]; subsequent studies have shown that all of the familial cases of prion disease are linked to *PRNP* mutations [1]. Moreover, over-expression of mutant *Prnp* in mice produces a transmissible neurodegenerative disorder similar to prion disease [24–28]. Strong evidence in favor of the prion hypothesis has come from the demonstration that *Prnp*^{-/-} mice are resistant to scrapie infection, and do not develop signs of the disease, or allow propagation of the infectious agent [29]. The cell-free conversion of PrP^C into PrP^{res} that is catalyzed by the pathological protein also provides support for the prion hypothesis. In this system, developed by Caughey and co-workers [30], purified PrP^C mixed with stoichiometric amounts of purified PrP^{Sc} produce a low

yield of PrP^{res} formation under non-physiological conditions, which precludes infectivity studies. In 2001, we developed a new system for *in vitro* replication of prions, termed protein misfolding cyclic amplification (PMCA) [31]. PMCA reproduces prion conversion in a greatly accelerated and efficient manner [31]. The *in vitro*-generated material maintains all the biological, biochemical and structural characteristics of *in-vivo*-produced prions [32]. These findings have confirmed a central tenet of the prion hypothesis, which is that prions can propagate indefinitely and that newly generated PrP^{Sc} triggers further misfolding to produce an auto-catalytic process of prion replication.

Is the prion hypothesis proven?

Despite the compelling evidence for the prion hypothesis, skeptics have argued that definitive proof cannot be achieved until infectious material is produced *in vitro* from pure, normal prion protein [33]. Such an experiment remained elusive for many years. However, in 2004 the production of 'synthetic prions' via the *in vitro* induction of misfolding and aggregation of bacterially expressed recombinant prion protein (rPrP) was reported [34]. Injection of this material into transgenic mice that overexpress PrP induces a transmissible neurodegenerative disease with a

very long incubation period. The generated infectious material displays different characteristics compared to those of natural prions. The authors proposed that conformational adaptation must have occurred to stabilize the originally extremely low infectivity of misfolded rPrP, which paradoxically involves a decrease in the thermodynamic stability of the aggregate [35]. These findings and subsequent studies from the same group [35–37], including the formation of many novel synthetic prions and even some composed of protease-sensitive PrP, have come very close to providing the definitive proof for the prion hypothesis. Unfortunately, the fact that the disease is transmissible only to transgenic animals that overexpress PrP, and not to wild-type animals, is a matter of concern, given the well-known propensity for such animals to develop a prion-like disease spontaneously [38–40]. In other words, the disease in these animals might have resulted by acceleration, induced by the injected material, of a pre-existing condition produced by transgenesis, as is the case in transgenic mice that overexpress mutant PrP [28]. Recent work using a different protocol to induce misfolding and aggregation of rPrP has generated infectious prions after several passages [41]. Importantly, this study demonstrated induction of disease in wild-type animals.

PMCA has proven to be a very successful technique for generation of *bona fide* infectious prions *in vitro*. Using PMCA, our group generated prions *in vitro* that were infectious to wild-type animals and displayed similar properties to brain-derived infectious material [32]. PMCA has become an invaluable technique to study prions, given that it provides the equivalent to a procedure for cultivating prions *in vitro*. In an extension of this work, Supattapone and colleagues generated infectious material using PMCA and PrP^C and PrP^{Sc} purified from the brain of healthy and sick animals, respectively [42]. Infectivity was generated in the absence of any other component besides the purified proteins and a synthetic polyanion that was used to catalyze the reaction. Importantly, this study, as well as a recent one from our group, showed that PMCA can generate *de novo* infectious PrP^{Sc} in the absence of any infectious brain-derived material to begin the reaction [42,43]. When spontaneously generated prions are injected into wild-type animals, the disease exhibits unique clinical, neuropathological and biochemical characteristics that differ from those of all previously known prions. An important question to be answered by future research is whether the *de novo* prions are present in the normal brain or are generated during the amplification process. A recent study that has shown the spontaneous generation of prions amplified by prion replication in cells also highlights this important issue [44]. In this study, infectivity was detectable at low frequency after incubation of uninfected mouse brain homogenate with metal wires that presumably concentrate prions. These remarkable findings lend strong support to the prion hypothesis, and provide a mechanistic explanation for the sporadic form of prion diseases. Moreover, they suggest that new forms of prions with different disease characteristics will probably appear in the future. All these PMCA studies were performed using mammalian PrP^C as a substrate. Formation of protease-resistant PrP from protein recombinantly produced in bacteria, seeded by

brain PrP^{Sc}, was first achieved by Atarashi *et al.*, by using an adapted version of PMCA [45]. Although material generated in this way is infectious to wild-type animals, it requires a long incubation period and results in an incomplete attack rate [46], which suggests that purified rPrP, in the absence of other cellular factors, is not capable of producing a highly infectious preparation. However, in a recent and elegant study, Wang *et al.* reported the *de novo* generation of *bona fide* infectious prions *in vitro* by PMCA using exclusively rPrP with the sole addition of RNA and lipids [47]. This study might represent the strongest proof to date for the prion hypothesis.

One argument that has often been used against the prion hypothesis is the existence of prion strains [48]. Nearly all transmissible spongiform encephalopathies are known to exhibit various strains that are characterized by different incubation periods, clinical features and neuropathology [49]. For infectious diseases, different strains generally arise from mutations or polymorphisms in the genetic make-up of the infectious agent. To reconcile the infectious agent that is composed exclusively of a protein with the strain phenomenon, it has been proposed that PrP^{Sc} obtained from different prion strains has slightly different conformation or aggregation states that can faithfully replicate at the expense of the host PrP^C [50–52]. This idea is supported by recent studies that have shown that a group of polythiophene compounds can differentially interact with PrP^{Sc} associated with distinct strains, thereby enabling them to be structurally distinguished [53]. Additional support for the hypothesis that the strain features are enciphered in the structure of PrP^{Sc} was provided by our recent study that has shown that PMCA can faithfully replicate different prion strains in humans and mice, which maintain all their features after multiple passages *in vivo* and *in vitro* [54]. Furthermore, the related phenomena of species barrier, strain adaptation, and molecular memory have also been reproduced *in vitro* by PMCA [55–57], which suggests again that they are dependent purely on PrP^{Sc} replication. When PrP^C from one species is used to replicate prions from a different species, new strains are generated, which points to an extremely high flexibility of PrP and raising the possibility of infinite ‘prionability’ of the protein.

Overall, the impressive recent progress in production of infectious material has removed all doubts about the prion hypothesis. In addition, the demonstration that several other proteins in a variety of organisms (such as yeast, fungi and invertebrates) use the prion mechanism to transmit biological information has strengthened the prion hypothesis (Box 1). Based on the available data, the idea that prions consist of viruses or any other type of conventional microorganism is simply untenable. Nevertheless, several key aspects of PrP^{Sc} infectivity remain unknown; particularly the detailed structure of the infectious protein, and whether or not another element besides the prion protein is required for prion replication.

Mechanism of prion replication and potential roles of co-factors in prion infectivity

Prion replication begins when PrP^{Sc} in the infectious material interacts with host PrP^C, thereby catalyzing its

Box 1. Yeast prions

The view that the transmission of biological information by propagation of protein misfolding was the exclusive domain of the rogue prion protein changed dramatically in 1994 when a visionary article from Reed Wickner proposed that the yeast proteins Ure2 and Sup35 behave like prions [86]. This article was followed by an impressive collection of studies that have demonstrated that these proteins indeed act as prions, and the identification of many other prions in yeasts and other fungi [87]. A yeast prion behaves as a non-Mendelian genetic element to transmit biological information in the absence of nucleic acid [88]. In yeast, prions do not kill the cells that harbor them, nor do they cause disease; rather, they are inherited by cellular division and usually produce new metabolic phenotypes. However, like their mammalian counterparts, yeast prions are based on the ability of a protein that has acquired an abnormal conformation to influence other molecules of the same protein to adopt the misfolded form. The discovery of the yeast prions was important not only to expand the prion concept towards proteins other than PrP, but also showed that prion transmission can be used for normal biological processes. Currently, it is unknown how many other proteins utilize a prion-based mechanism to perform their biological function, but it seems possible that the efficient conversion of a protein function by transmission of an alternative folding state could provide an excellent way in which to modulate the activity of proteins without the need for genetic changes [87].

conversion to the pathogenic form of the protein. The precise molecular mechanism of $\text{PrP}^{\text{C}} \rightarrow \text{PrP}^{\text{Sc}}$ conversion is not completely understood, but available data support a seeding/nucleation model in which infectious PrP^{Sc} is an oligomer that acts as a seed to bind PrP^{C} and catalyze its conversion into the misfolded form by incorporation into the growing polymer [58–60]. At some point, the long PrP^{Sc} polymers break into smaller pieces driven by a mechanical force or catalyzed by a yet-unknown process. This fragmentation increases the number of effective nuclei that can direct further conversion of PrP^{C} . Polymer fragmentation is probably a rate-limiting event in prion replication, therefore, it is important to understand how this occurs *in vivo*, and whether another cellular factor participates in this process. The seeding–nucleation model provides a rational and plausible explanation for the infectious nature of prions. Infectivity relies on the capacity of pre-formed stable misfolded oligomeric PrP^{Sc} to act as a seed to catalyze the misfolding and aggregation process [60]. Indeed, the PMCA technology is based on the assumption that prion replication depends on the formation and multiplication of oligomeric seeds [31,59].

An open question in the field is whether or not prion replication requires a cellular co-factor. Several pieces of evidence indicate that co-factors might participate in prion replication [61]. The existence of a host-encoded conversion factor was first suspected from experiments with transgenic mice that expressed chimeric prion proteins from two different species [62]. Based on these findings, Prusiner coined the term ‘protein X’ to refer to this factor; however, there is no formal proof that the accessory molecule is indeed a protein. Further evidence for the existence of conversion factors came from PMCA studies of $\text{PrP}^{\text{C}} \rightarrow \text{PrP}^{\text{Sc}}$ conversion. Purified hamster PrP^{C} is not converted when mixed with highly purified PrP^{Sc} ; however, conversion is restored when the complete brain homogenate is added to the sample [63–65]. These results suggest that

unknown factors present in brain homogenate are essential for prion conversion. Supattapone’s group has shown that natural or synthetic RNA can act as conversion factors and catalyze prion replication in hamsters [66], but surprisingly, not in mice [67]. It has been proposed that RNA might serve as a scaffold for efficient conversion and a necessary molecular complex-pair as the minimal infectious unit [68]. These data suggest that nucleic acids might be, after all, involved in prion replication. However, an alternative possibility is that RNA only accelerates or stabilizes an otherwise experimentally inaccessible PrP^{Sc} -like conformation. The same group has shown that it is the negative charge of RNA that is responsible for the interaction with PrP, given that several other natural or synthetic polyanions can have the same activity [64]. These results, however, do not fit with the initial finding that only eukaryotic RNA, and not prokaryotic RNA, assists prion conversion [66]. More recent studies have shown that replication of PrP^{Sc} and infectivity that stems from rPrP require synthetic anionic phospholipids in addition to RNA [47]. The requirement for lipids is consistent with previous studies that have reported higher infectivity with lipid-membrane-associated PrP^{Sc} [69,70]. In spite of these findings, it is possible that RNA and lipids are merely *in vitro* mimics of the activity of one or more unknown *in vivo* facilitating factors. Recent attempts to identify the mysterious co-factor, using a complementation PMCA assay and fractionation techniques, have shown that it is present in all major organs of diverse mammalian species, and is predominantly located in the lipid raft fraction of the cytoplasmic membrane [65]. However, conversion factor activity is not present in the lower organisms tested (yeast, bacteria and flies), which suggests that prion replication is a feature that is only present in mammals. Surprisingly, treatments that eliminate nucleic acids, proteins or lipids do not prevent prion replication *in vitro* [65]. One possible interpretation of these findings is that various different compounds might act as a conversion factor *in vitro*, such that elimination of only some of them does not prevent prion replication. Indeed, the addition of various classes of molecules (synthetic nucleic acids, heparin, albumin or fatty acids) produces a small but detectable effect on enhancing prion replication *in vitro* [65].

If co-factors are indeed necessary for prion replication, it is possible to imagine at least five possible roles played by these accessory molecules (Figure 2):

- (i) The co-factor might contribute biological information to the infectious material. If the accessory molecule is incorporated into the PrP^{Sc} particles, it is possible that it could help to determine the folding characteristics of prions. In addition, it might facilitate the interaction with cellular components and modify the tropism of the infectious agent. In this case, the co-factor could have an important role in modulating the properties of prion strains. A recent study provided indirect evidence for this possibility [71]. Experiments using a panel of cells to replicate mouse prions have shown that infection of different cell types leads to phenotypic “mutation” and selection of prion strains. One possible explanation for these results is that cellular diversity in co-factors could direct




Figure 2. Possible roles by which co-factors might participate in prion replication. At least five different scenarios can be proposed for the involvement of cellular co-factors in prion propagation. **(a)** The co-factor might integrate into the infectious agent, alter PrP^{Sc} folding, and provide biological information to the infectivity process, perhaps by determining strain characteristics. **(b)** The co-factor might act as an essential catalyst for prion replication, perhaps by interacting with PrP^C, altering its folding, and permitting its interaction with PrP^{Sc}. **(c)** Through binding and integration into the PrP^{Sc} polymer, the co-factor might help to stabilize the conformation of PrP^{Sc}. **(d)** The co-factor might participate in the key process of fragmenting PrP^{Sc} polymers to produce smaller structures, and multiplying the number of seeds to allow the continuation of prion replication. **(e)** The co-factor might bind to PrP^{Sc}, thus increasing its biological stability, reducing its clearance *in vivo*, and increasing its chances to reach target organs. It is important to highlight that these possibilities are not mutually exclusive, and indeed, it is likely that a co-factor could be involved in several of these processes simultaneously.

- prion strain changes, given that no differences in PrP were detected between the different cells [72].
- (ii) The co-factor might act as an essential catalyst for prion replication. The conversion factor could facilitate the PrP^C to PrP^{Sc} conversion, perhaps by directing the interaction of the two proteins, or through binding to PrP^C and inducing a partial unfolding of the protein that is necessary to adopt the misfolded conformation. The idea that co-factors facilitate prion replication is supported by *in vitro* conversion experiments that have shown that the PrP^C to PrP^{Sc} conversion is more efficient in the presence of accessory molecules [47,65,67].
 - (iii) The co-factor might help to stabilize the conformation of PrP^{Sc}. In this model, although the co-factor does not directly participate in the conformational conversion, it might contribute to stabilization of the newly formed misfolded structure. This view is supported by neuropathological data, especially from other neurodegenerative diseases, which show that attachment of

- a variety of molecules (e.g. proteins, nucleic acids, metal ions, or proteoglycans) to cerebral protein aggregates makes them much more compact and stable structures [73–75].
- (iv) The co-factor might participate in the fragmentation of PrP^{Sc} polymers. As described above, prion replication follows a seeding–nucleation process of polymerization. For this process of seeding–nucleation to propagate prions efficiently, it is necessary not only for PrP^C to be able to seed the misfolding and aggregation of PrP^C, but also for long polymers to be fragmented into smaller pieces as a way to increase the effective number of seeds that catalyze prion replication. Indeed, in yeast prions (Box 1), the chaperone heat shock protein 104 (Hsp104) probably fulfills this role [76,77], given that the replication of most yeast prions depends on this factor and that inhibition of Hsp104 activity precludes prion propagation [78].
- (v) The co-factor might increase the biological stability of prions, thereby reducing their *in vivo* clearance.

Another possibility is that the co-factor increases the pharmacokinetic and bioavailability properties of PrP^{Sc}. In this sense, it is important to emphasize that the ability of an infectious agent to propagate disease depends not only on its successful replication, but also on its ability to remain intact in the body and reach the target location. This is a challenging task for an infectious agent that is composed solely of a protein. Recent studies have identified a possible pathway for prion clearance that involves milk fat globule-EGF factor 8 protein (MFGES)-mediated phagocytosis of prions by microglia [79]. In this context, a co-factor could reduce the affinity of PrP^{Sc} for MFGES, thereby decreasing the ability of microglia to engulf and destroy prions. The possibility that the co-factor contributes to the biological stability of PrP^{Sc} is in agreement with results that have shown that attachment of prions to nitrocellulose paper, soil particles or steel wires increases prion infectivity [80–82].

One of the most important issues related to the existence of possible components other than PrP that are involved in prion transmission is to distinguish between factors contained in the infectious particle and host factors that are involved in the conformational change. This distinction is very relevant; if additional factors must be part of the infectious particle, then the infectious units would not be composed solely of PrP^{Sc}. Alternatively, additional factors might need to be present in the host cells to sustain efficient prion replication. These factors could be normal cellular components that are presumably engaged in other functions in the infected cells, which accidentally participate in prion conversion. In the latter case, these additional factors should not be considered part of the infectious particle, but rather host-encoded molecules that facilitate prion replication.

Concluding remarks

The hypothesis that a single protein is the sole component of the infectious agent responsible for prion diseases has been highly controversial for the past 30 years. This is not surprising considering that the prion hypothesis claims that a protein behaves like a living microorganism to infect an individual by various routes (even oral administration), survive metabolic clearance, self-replicate in the body, reach the target organ, and induce a cascade of neurodegenerative damage, which results in disease and ultimately death of the infected individual. Moreover, the prion agent exists as multiple strains that lead to diseases with sometimes subtle and other times overtly different clinical and neuropathological characteristics. Prion propagation also respects the still incompletely understood rules of species barriers and exhibits characteristics of strain adaptation and memory. All of these features can be easily explained by an agent that contains genetic material, but a protein-based infectious agent makes an explanation more challenging. For this reason, although compelling evidence has accumulated steadily to support the prion hypothesis, the majority of scientists have remained skeptical. However, exciting research in the past 3 years has demonstrated that infectious material can be generated with defined

components *in vitro*, and that the information for strains and the species barrier appears to be exclusively contained in the folding of PrP^{Sc}. These findings have proven beyond any doubt that the prion hypothesis is indeed correct. This does not mean that everything is known regarding prions. On the contrary, there are many outstanding questions still unanswered (Box 3). Among these, it is particularly important to understand whether or not other cellular factors play a role in prion replication. This is not simply a matter of curiosity; it is crucial to understand the nature of the infectious agent. In this context we are still uncertain whether the prion hypothesis is equivalent to a PrP^{Sc}-only hypothesis. Although it is clear that PrP^{Sc} is the main informational molecule in the infectious agent, it remains possible that a co-factor is required, perhaps to achieve efficient propagation in the *in vivo* setting. In the latter scenario, a molecule other than PrP^{Sc} would be essential for infectivity. Nevertheless, the putative existence of a co-factor, and its potential role in the process, does not negate the protein-based mechanism of transmission by which prions produce disease. Another important area of research is to elucidate the 3D structure of PrP^{Sc} and determine the structural features of prion strains. The remarkable progress in the generation of infectious prions from purified components, owing to the successful application of the PMCA technique, opens the possibility to produce large amounts of chemically homogeneous and metabolically labeled infectious PrP^{Sc}, which paves the way to fine structural studies.

The advances in the prion hypothesis have paralleled the expansion of the prion concept beyond prion diseases. Indeed, recent years have witnessed the end of a period of skepticism surrounding the possibility that a single protein could act as an infectious agent, and the beginning of

Box 2. Transmission of other diseases by a prion-based mechanism

Misfolded protein aggregates are associated not only with prion diseases, but also with a large group of diseases that are known as protein misfolding disorders (PMDs), which include some highly prevalent and insidious illnesses such as Alzheimer's disease, Parkinson's disease, type 2 diabetes and over 20 additional human maladies [89,90]. Compelling evidence suggests that the accumulation of misfolded protein aggregates triggers tissue damage, organ dysfunction and disease in all of these PMDs. To date, only prion disorders are considered to be transmissible. However, the molecular mechanisms responsible for protein misfolding and aggregation are remarkably similar in all PMDs [60]. Indeed, the formation of misfolded aggregates in all cases follows a seeding-nucleation model, which can be accelerated by the addition of preformed seeds. The ability of seeds to template misfolding and aggregation is the key element of prion transmissibility, and this similarity suggests that all PMDs have the intrinsic potential to be transmissible [60]. Strikingly, reports from the past 3 years, using cellular and/or animal models, have provided evidence to suggest that the transmission of protein misfolding by a prion-like mechanism might be at the heart of the most common PMDs, including Alzheimer's, Parkinson's and Huntington's diseases [84,91–94]. The exciting goal of future research is to determine if the misfolded proteins that are implicated in PMDs are infectious, and if they transmit disease under natural conditions. In other words, we need to assess carefully whether misfolded proteins are transmitted between individuals and propagate within communities as conventional infectious agents.

Box 3. Outstanding questions

- Is PrP^{Sc} the only component of the infectious prion agent?
- What is the nature and role of cellular co-factors in prion replication?
- What is the 3D structure of PrP^{Sc}?
- What is the normal function of PrP^C? Does it have anything to do with the conformational flexibility of the protein?
- How is the prion strain phenomenon enciphered in the structure of PrP^{Sc}?
- How does PrP^{Sc} induce brain degeneration?
- To what extent does the prion principle operate in other diseases of protein misfolding?
- How common is the prion phenomenon in nature?
- Do prion-like proteins exist in mammals which confer advantageous properties to their hosts?

an era in which the prion phenomenon is being expanded to some of the most prevalent human diseases (Box 2) [60,83–85]. If further research proves that several other diseases can be transmitted by the propagation of misfolded proteins, prions could turn out to be more than a rare caprice of nature.

Acknowledgments

I would like to thank Rodrigo Diaz-Espinoza (University of Texas Medical School at Houston) for stimulating discussions regarding the potential roles of co-factors in prion replication. This work was supported in parts by NIH grants R01 NS049173 and P01 IA077774 to CS.

References

- 1 Collinge, J. (2001) Prion diseases of humans and animals: their causes and molecular basis. *Annu. Rev. Neurosci.* 24, 519–550
- 2 Cullie, J. and Chelle, P.L. (1939) Experimental transmission of trembling to the goat. *Comptes Rendus des Seances de l'Academie des Sciences* 208, 1058–1160
- 3 Chandler, R.L. (1961) Encephalopathy in mice produced by inoculation with scrapie brain material. *Lancet* 1, 1378–1379
- 4 Gajdusek, D.C. *et al.* (1966) Experimental transmission of a Kuru-like syndrome to chimpanzees. *Nature* 209, 794–796
- 5 Gibbs, C.J., Jr *et al.* (1968) Creutzfeldt–Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. *Science* 161, 388–389
- 6 Masters, C.L. *et al.* (1981) Creutzfeldt–Jakob disease virus isolations from the Gerstmann–Straussler syndrome with an analysis of the various forms of amyloid plaque deposition in the virus-induced spongiform encephalopathies. *Brain* 104, 559–588
- 7 Bradley, R. (1991) Bovine spongiform encephalopathy (BSE): the current situation and research. *Eur. J. Epidemiol.* 7, 532–544
- 8 Will, R.G. *et al.* (1996) A new variant of Creutzfeldt–Jakob disease in the UK. *Lancet* 347, 921–925
- 9 Hill, A.F. *et al.* (1997) The same prion strain causes vCJD and BSE. *Nature* 389, 448–450
- 10 Alper, T. *et al.* (1967) Does the agent of scrapie replicate without nucleic acid? *Nature* 214, 764–766
- 11 Alper, T. (1993) The scrapie enigma: insights from radiation experiments. *Radiat. Res.* 135, 283–292
- 12 Alper, T. *et al.* (1966) The exceptionally small size of the scrapie agent. *Biochem. Biophys. Res. Commun.* 22, 278–284
- 13 Silveira, J.R. *et al.* (2005) The most infectious prion protein particles. *Nature* 437, 257–261
- 14 Pattison, I.H. and Jones, K.M. (1967) The possible nature of the transmissible agent of scrapie. *Vet. Rec.* 80, 2–9
- 15 Griffith, J.S. (1967) Self-replication and scrapie. *Nature* 215, 1043–1044
- 16 Prusiner, S.B. (1982) Novel proteinaceous infectious particles cause scrapie. *Science* 216, 136–144
- 17 Bolton, D.C. *et al.* (1982) Identification of a protein that purifies with the scrapie prion. *Science* 218, 1309–1311
- 18 Gabizon, R. *et al.* (1988) Immunoaffinity purification and neutralization of scrapie prion infectivity. *Proc. Natl. Acad. Sci. U. S. A.* 85, 6617–6621
- 19 Oesch, B. *et al.* (1985) A cellular gene encodes scrapie PrP 27–30 protein. *Cell* 40, 735–746
- 20 Chesebro, B. *et al.* (1985) Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. *Nature* 315, 331–333
- 21 Basler, K. *et al.* (1986) Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. *Cell* 46, 417–428
- 22 Stahl, N. *et al.* (1993) Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. *Biochemistry* 32, 1991–2002
- 23 Hsiao, K. *et al.* (1989) Linkage of a prion protein missense variant to Gerstmann–Straussler syndrome. *Nature* 338, 342–345
- 24 Hsiao, K.K. *et al.* (1990) Spontaneous neurodegeneration in transgenic mice with mutant prion protein. *Science* 250, 1587–1590
- 25 Jackson, W.S. *et al.* (2009) Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. *Neuron* 63, 438–450
- 26 Sigurdson, C.J. *et al.* (2009) *De novo* generation of a transmissible spongiform encephalopathy by mouse transgenesis. *Proc. Natl. Acad. Sci. U. S. A.* 106, 304–309
- 27 Telling, G.C. *et al.* (1996) Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. *Genes Dev.* 10, 1736–1750
- 28 Nazor, K.E. *et al.* (2005) Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. *EMBO J.* 24, 2472–2480
- 29 Bueler, H. *et al.* (1993) Mice devoid of PrP are resistant to scrapie. *Cell* 73, 1339–1347
- 30 Kocisko, D.A. *et al.* (1994) Cell-free formation of protease-resistant prion protein. *Nature* 370, 471–474
- 31 Saborio, G.P. *et al.* (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. *Nature* 411, 810–813
- 32 Castilla, J. *et al.* (2005) *In vitro* generation of infectious scrapie prions. *Cell* 121, 195–206
- 33 Soto, C. and Castilla, J. (2004) The controversial protein-only hypothesis of prion propagation. *Nat. Med.* 10, S63–S67
- 34 Legname, G. *et al.* (2004) Synthetic mammalian prions. *Science* 305, 673–676
- 35 Legname, G. *et al.* (2005) Strain-specified characteristics of mouse synthetic prions. *Proc. Natl. Acad. Sci. U. S. A.* 102, 2168–2173
- 36 Colby, D.W. *et al.* (2009) Design and construction of diverse mammalian prion strains. *Proc. Natl. Acad. Sci. U. S. A.* 106, 20417–20422
- 37 Colby, D.W. *et al.* (2010) Protease-sensitive synthetic prions. *PLoS Pathog.* 6, e1000736
- 38 Westaway, D. *et al.* (1994) Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. *Cell* 76, 117–129
- 39 Castilla, J. *et al.* (2004) Subclinical bovine spongiform encephalopathy infection in transgenic mice expressing porcine prion protein. *J. Neurosci.* 24, 5063–5069
- 40 Chiesa, R. *et al.* (1998) Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. *Neuron* 21, 1339–1351
- 41 Makarava, N. *et al.* (2010) Recombinant prion protein induces a new transmissible prion disease in wild-type animals. *Acta Neuropathol.* 119, 177–187
- 42 Deleault, N.R. *et al.* (2007) Formation of native prions from minimal components *in vitro*. *Proc. Natl. Acad. Sci. U. S. A.* 104, 9741–9746
- 43 Barria, M.A. *et al.* (2009) *De novo* generation of infectious prions *in vitro* produces a new disease phenotype. *PLoS Pathog.* 5, e1000421
- 44 Edgeworth, J.A. *et al.* (2010) Spontaneous generation of mammalian prions. *Proc. Natl. Acad. Sci. U. S. A.* 107, 14402–14406
- 45 Atarashi, R. *et al.* (2007) Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. *Nat. Methods* 4, 645–650
- 46 Kim, J.I. *et al.* (2010) Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. *J. Biol. Chem.* 285, 14083–14087
- 47 Wang, F. *et al.* (2010) Generating a prion with bacterially expressed recombinant prion protein. *Science* 327, 1132–1135
- 48 Chesebro, B. (1998) BSE and prions: uncertainties about the agent. *Science* 279, 42–43
- 49 Morales, R. *et al.* (2007) The prion strain phenomenon: molecular basis and unprecedented features. *Biochim. Biophys. Acta* 1772, 681–691

- 50 Bessen, R.A. *et al.* (1995) Non-genetic propagation of strain-specific properties of scrapie prion protein. *Nature* 375, 698–700
- 51 Safar, J. *et al.* (1998) Eight prion strains have PrP(Sc) molecules with different conformations. *Nat. Med.* 4, 1157–1165
- 52 Telling, G.C. *et al.* (1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. *Science* 274, 2079–2082
- 53 Sigurdson, C.J. *et al.* (2007) Prion strain discrimination using luminescent conjugated polymers. *Nat. Methods* 4, 1023–1030
- 54 Castilla, J. *et al.* (2008) Cell-free propagation of prion strains. *EMBO J.* 27, 2557–2566
- 55 Castilla, J. *et al.* (2008) Crossing the species barrier by PrP(Sc) replication *in vitro* generates unique infectious prions. *Cell* 134, 757–768
- 56 Green, K.M. *et al.* (2008) Accelerated high fidelity prion amplification within and across prion species barriers. *PLoS Pathog.* 4, e1000139
- 57 Meyerett, C. *et al.* (2008) *In vitro* strain adaptation of CWD prions by serial protein misfolding cyclic amplification. *Virology* 382, 267–276
- 58 Caughey, B. (2003) Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains. *Br. Med. Bull.* 66, 109–120
- 59 Soto, C. *et al.* (2002) Cyclic amplification of protein misfolding: application to prion-related disorders and beyond. *Trends Neurosci.* 25, 390–394
- 60 Soto, C. *et al.* (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. *Trends Biochem. Sci.* 31, 150–155
- 61 Abid, K. and Soto, C. (2006) The intriguing prion disorders. *Cell Mol. Life Sci.* 63, 2342–2351
- 62 Telling, G.C. *et al.* (1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. *Cell* 83, 79–90
- 63 Saborio, G.P. *et al.* (1999) Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. *Biochem. Biophys. Res. Commun.* 258, 470–475
- 64 Deleault, N.R. *et al.* (2005) Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. *J. Biol. Chem.* 280, 26873–26879
- 65 Abid, K. *et al.* (2010) Cellular factors implicated in prion replication. *FEBS Lett.* 584, 2409–2414
- 66 Deleault, N.R. *et al.* (2003) RNA molecules stimulate prion protein conversion. *Nature* 425, 717–720
- 67 Deleault, N.R. *et al.* (2010) Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein *in vitro*. *Biochemistry* 49, 3928–3934
- 68 Geoghegan, J.C. *et al.* (2007) Selective incorporation of polyanionic molecules into hamster prions. *J. Biol. Chem.* 282, 36341–36353
- 69 Gabizon, R. *et al.* (1987) Purified prion proteins and scrapie infectivity copartition into liposomes. *Proc. Natl. Acad. Sci. U. S. A.* 84, 4017–4021
- 70 Baron, G.S. *et al.* (2006) Mouse-adapted scrapie infection of SN56 cells: greater efficiency with microsome-associated versus purified PrP-res. *J. Virol.* 80, 2106–2117
- 71 Li, J. *et al.* (2010) Darwinian evolution of prions in cell culture. *Science* 327, 869–872
- 72 Weissmann, C. (2009) Thoughts on mammalian prion strains. *Folia Neuropathol.* 47, 104–113
- 73 Tennent, G.A. *et al.* (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. *Proc. Natl. Acad. Sci. U. S. A.* 92, 4299–4303
- 74 Castillo, G.M. *et al.* (1997) Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. *J. Neurochem.* 69, 2452–2465
- 75 Soto, C. *et al.* (1997) Alzheimer's amyloid- β aggregation is modulated by the interaction of multiple factors. *Alzheimer's Res.* 3, 215–222
- 76 Bosl, B. *et al.* (2006) The molecular chaperone Hsp104-A molecular machine for protein disaggregation. *J. Struct. Biol.* 156, 139–148
- 77 Kryndushkin, D.S. *et al.* (2003) Yeast [PSI⁺] prion aggregates are formed by small Sup35 polymers fragmented by Hsp104. *J. Biol. Chem.* 278, 49636–49643
- 78 Ferreira, P.C. *et al.* (2001) The elimination of the yeast [PSI⁺] prion by guanidine hydrochloride is the result of Hsp104 inactivation. *Mol. Microbiol.* 40, 1357–1369
- 79 Kranich, J. *et al.* (2010) Engulfment of cerebral apoptotic bodies controls the course of prion disease in a mouse strain-dependent manner. *J. Exp. Med.* 207, 2271–2281
- 80 Weber, P. *et al.* (2007) Generation of genuine prion infectivity by serial PMCA. *Vet. Microbiol.* 123, 346–357
- 81 Johnson, C.J. *et al.* (2007) Oral transmissibility of prion disease is enhanced by binding to soil particles. *PLoS Pathog.* 3, e93
- 82 Yan, Z.X. *et al.* (2004) Infectivity of prion protein bound to stainless steel wires: a model for testing decontamination procedures for transmissible spongiform encephalopathies. *Infect. Control Hosp. Epidemiol.* 25, 280–283
- 83 Aguzzi, A. (2009) Cell biology: beyond the prion principle. *Nature* 459, 924–925
- 84 Brundin, P. *et al.* (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. *Nat. Rev. Mol. Cell Biol.* 11, 301–307
- 85 Frost, B. and Diamond, M.I. (2010) Prion-like mechanisms in neurodegenerative diseases. *Nat. Rev. Neurosci.* 11, 155–159
- 86 Wickner, R.B. (1994) [URE3] as an altered URE2 protein: evidence for a prion analog in *Saccharomyces cerevisiae*. *Science* 264, 566–569
- 87 Halfmann, R. *et al.* (2010) Prions, protein homeostasis, and phenotypic diversity. *Trends Cell Biol.* 20, 125–133
- 88 Lindquist, S. (1997) Mad cows meet psi-chotic yeast: the expansion of the prion hypothesis. *Cell* 89, 495–498
- 89 Soto, C. (2001) Protein misfolding and disease; protein refolding and therapy. *FEBS Lett.* 498, 204–207
- 90 Chiti, F. and Dobson, C.M. (2006) Protein misfolding, functional amyloid, and human disease. *Annu. Rev. Biochem.* 75, 333–366
- 91 Meyer-Luehmann, M. *et al.* (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science* 313, 1781–1784
- 92 Clavaguera, F. *et al.* (2009) Transmission and spreading of tauopathy in transgenic mouse brain. *Nat. Cell Biol.* 11, 909–913
- 93 Ren, P.H. *et al.* (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. *Nat. Cell Biol.* 11, 219–225
- 94 Frost, B. *et al.* (2009) Propagation of tau misfolding from the outside to the inside of a cell. *J. Biol. Chem.* 284, 12845–12852